Prior to 2011, the 1-year survival rates for patients suffering from advanced or metastatic melanoma was as low as 33%, with a median overall survival of about 9 months. Several chemotherapeutic regimens have been applied, either as monochemotherapy or as poly-chemotherapy, overall not resulting in an improvement of progression-free or overall survival. Novel insights into the epidemiology and biology of melanoma allowed the development of newer therapies. The discovery of mutations in BRAF, a part of the mitogen-activated protein kinase, allowed the development of two BRAF inhibitors, vemurafenib and dabrafenib, which significantly improved the outcome of metastatic melanoma treatment. This article reviews the mechanism of action, efficacy, and safety profile of dabrafenib. An in-depth knowledge of this medication will encourage clinicians to select the appropriate therapeutic strategy for each patient, as well as to prevent or adequately manage side effects, optimizing, thus, the drug’s applicability.

Dabrafenib: A new opportunity for the treatment of BRAFV600-positive melanoma / Banzi, Maria; de Blasio, Simona; Lallas, Aimilios; Longo, Caterina; Moscarella, Elvira; Alfano, Roberto; Argenziano, Giuseppe. - In: ONCOTARGETS AND THERAPY. - ISSN 1178-6930. - 9:(2016), pp. 2725-2733. [10.2147/OTT.S75104]

Dabrafenib: A new opportunity for the treatment of BRAFV600-positive melanoma

LONGO, Caterina;MOSCARELLA, ELVIRA;ARGENZIANO, GIUSEPPE
2016

Abstract

Prior to 2011, the 1-year survival rates for patients suffering from advanced or metastatic melanoma was as low as 33%, with a median overall survival of about 9 months. Several chemotherapeutic regimens have been applied, either as monochemotherapy or as poly-chemotherapy, overall not resulting in an improvement of progression-free or overall survival. Novel insights into the epidemiology and biology of melanoma allowed the development of newer therapies. The discovery of mutations in BRAF, a part of the mitogen-activated protein kinase, allowed the development of two BRAF inhibitors, vemurafenib and dabrafenib, which significantly improved the outcome of metastatic melanoma treatment. This article reviews the mechanism of action, efficacy, and safety profile of dabrafenib. An in-depth knowledge of this medication will encourage clinicians to select the appropriate therapeutic strategy for each patient, as well as to prevent or adequately manage side effects, optimizing, thus, the drug’s applicability.
2016
9
2725
2733
Dabrafenib: A new opportunity for the treatment of BRAFV600-positive melanoma / Banzi, Maria; de Blasio, Simona; Lallas, Aimilios; Longo, Caterina; Moscarella, Elvira; Alfano, Roberto; Argenziano, Giuseppe. - In: ONCOTARGETS AND THERAPY. - ISSN 1178-6930. - 9:(2016), pp. 2725-2733. [10.2147/OTT.S75104]
Banzi, Maria; de Blasio, Simona; Lallas, Aimilios; Longo, Caterina; Moscarella, Elvira; Alfano, Roberto; Argenziano, Giuseppe
File in questo prodotto:
File Dimensione Formato  
OTT-75104-dabrafenib--a-new-opportunity-for-the-treatment-of-braf-v600_050616.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 1.29 MB
Formato Adobe PDF
1.29 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1140867
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 29
social impact